Antonio Galvano

ORCID: 0000-0003-4365-5683
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Gastric Cancer Management and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Gastrointestinal Tumor Research and Treatment
  • PARP inhibition in cancer therapy
  • Hepatocellular Carcinoma Treatment and Prognosis
  • BRCA gene mutations in cancer
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Cancer-related molecular mechanisms research
  • Genetic factors in colorectal cancer
  • Extracellular vesicles in disease
  • Neuroendocrine Tumor Research Advances
  • MicroRNA in disease regulation
  • DNA Repair Mechanisms
  • Sarcoma Diagnosis and Treatment
  • Bone health and treatments
  • Lung Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Peptidase Inhibition and Analysis
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Nanoplatforms for cancer theranostics

University of Palermo
2016-2025

University of Palermo
2016-2023

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo
2016-2023

Fondazione Salvatore Maugeri
2018

Weatherford College
2013

// Francesco Passiglia 1, * , Giuseppe Bronte Viviana Bazan Clara Natoli 2 Sergio Rizzo 1 Antonio Galvano Angela Listì Cicero Christian Rolfo 3 Daniele Santini 4 Russo Section of Medical Oncology, Department Surgical, Oncological and Oral Sciences, University Palermo, Italy Medical, Biotechnological "G. D'Annunzio", Chieti, Phase I- Early Clinical Trials Unit, Oncology Multidisciplinary Center Antwerp (MOCA), Hospital, Edegem, Belgium Department, Campus Biomedico, Rome, These authors have...

10.18632/oncotarget.7582 article EN Oncotarget 2016-02-22

Background: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC). Methods: A total 45 receiving 3 mg/kg every 2 weeks were enrolled. Patients underwent a computed tomography scan and responses evaluated by response evaluation criteria solid tumors. Peripheral blood samples obtained from cfDNA level NLR...

10.1177/1758835919839928 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2019-01-01

Since their introduction in orthodontics, clear aligners have been appreciated by patients, including adults, for comfort and low aesthetic impact. Despite the enormous mobilization of financial resources all over world aimed at producing new product lines, few clinical studies or high-quality evidence produced regarding real effectiveness such treatment. Given limited kinds research on subject, this study aims to produce critically evaluate other data, establish concrete reliability...

10.1186/s40510-022-00406-7 article EN cc-by Progress in Orthodontics 2022-04-10

Background: Lung neuroendocrine carcinoma (NEC) is characterized by aggressive clinical behavior and lack of treatment advances. We evaluate the prognostic predictive roles systemic inflammatory biomarkers in patient circulating blood: neutrophil–lymphocyte ratio (NLR), lactate dehydrogenase (LDH), advanced lung cancer inflammation index (ALI), Immune Prognostic Index (LIPI) score. Methods: A total 120 patients with small-cell (SCLC) ( n = 110) large cell (LCNEC) 10) were enrolled. Overall...

10.1177/1758835920942378 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2020-01-01

OPINION article Front. Oncol., 23 April 2020Sec. Cancer Epidemiology and Prevention Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.00734

10.3389/fonc.2020.00734 article EN cc-by Frontiers in Oncology 2020-04-23

Despite the increasing implementation of targeted and immunotherapy-based treatments, prognosis patients with advanced NSCLC remains dismal. We prospectively evaluated longitudinal plasma cfDNA kinetics as an early marker therapeutic efficacy in undergoing standard first-line treatments.From February 2020 to May 2022, treatment-naïve were consecutively enrolled at Medical Oncology Unit Paolo Giaccone University Hospital, Palermo (Italy). quantified terms ng/μL using a QubitTM dsDNA HS Assay...

10.3390/cancers14236013 article EN Cancers 2022-12-06

Individual response to immune checkpoint inhibitors (ICIs) is currently unpredictable in patients with melanoma. Recent findings highlight a striking improvement the clinical outcomes of overweight/obese treated ICIs, which seems driven, at least part, by programmed cell death protein 1 (PD-1)-mediated T-cell dysfunction. A putative role butyrophilins (BTNs) under investigation as novel mechanism cancer evasion and obesity-associated inflammation. This study investigates baseline plasma...

10.1177/17588359231151845 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2023-01-01
Coming Soon ...